{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"16.7","upperLimit":"40.0","value":"38.9"}]}],"title":"Independent radiologist assessed, n=0, 11"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"22.6","upperLimit":"44.0","value":"32.1"}]}],"title":"Investigator assessed, n=0, 23"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the date of the first documented evidence of CR or PR until the date of either the first documented sign of PD or death due to any cause. Participants who neither died nor progressed were censored at the date of the last adequate radiologic assessment. The Kaplan-Meier method was used for duration of response estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only participants who achieved a confirmed CR or PR, as determined independently by the Independent Radiologist and the Investigator, were analyzed. Only results for the pazopanib arm are given because there was no response in the placebo arm.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)","title":"Duration of Response Assessed by the Independent Radiologist and the Investigator","type":"SECONDARY","unitOfMeasure":"weeks"}